Stifel Maintains Buy on Kymera Therapeutics, Raises Price Target to $152
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Stifel analyst Alex Thompson maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $132 to $152.
Stifel analyst Alex Thompson maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $132 to $152.